等待開盤 08-22 09:30:00 美东时间
+0.010
+1.01%
Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major
08-07 19:39
Clearmind Medicine Inc. and SciSparc Ltd. announced a joint international patent application under the PCT for a novel combination therapy targeting metabolic syndrome and obesity. This therapy combines Clearmind's MEAI and SciSparc's PEA, leveraging their complementary pharmacological properties. The collaboration, which has resulted in 13 patent families across multiple jurisdictions, aims to develop innovative treatments for mental health diso...
08-07 11:32
SciSparc Ltd. and Clearmind Medicine Inc. have filed a new international patent application for their innovative combination therapy targeting obesity and MASLD. The therapy combines 5-methoxy-2-aminoindane and N-Acylethanolamines (MEAI) with Palmitoylethanolamide (PEA), leveraging its unique pharmacological properties. The collaboration aims to address significant global health challenges, with obesity affecting over 890 million people and NAFLD...
07-30 12:12
Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major
07-23 20:56
Clearmind Medicine Inc. expands its Phase I/IIa trial for CMND-100, an oral treatment for Alcohol Use Disorder, by adding a site at Johns Hopkins University and enrolling its first participant there. The trial evaluates safety, tolerability, and pharmacokinetics, while assessing potential reductions in alcohol cravings and consumption. This follows the recent enrollment of the first participant at Yale School of Medicine, strengthening Clearmind’...
07-15 12:05
https://ppubs.uspto.gov/api/pdf/downloadPdf/12350242?requestToken=eyJzdWIiOiJlMmEyMTIwZi01YWZmLTQ5NGMtYjFkYi1lZTVmMmQ3MzM4NDgiLCJ2ZXIiOiJkNTc5MmM2MC00MzhmLTRkOGItODRjNy1iZWM5NjU2YjRjZTQiLCJleHAiOjB9
07-09 04:00
Clearmind Medicine Inc. received IRB approval from Tel Aviv Sourasky Medical Center for its Phase 1/2a clinical trial of CMND-100, a psychedelic-derived drug candidate for treating Alcohol Use Disorder (AUD). The trial, conducted at leading institutions including Yale, Johns Hopkins, and Hadassah-University Medical Center, aims to assess CMND-100's safety, tolerability, and efficacy in reducing alcohol cravings. The approval marks a significant s...
07-03 12:47
Clearmind Medicine Inc. announced a historic milestone as the first participant was dosed with its proprietary CMND-100, an oral psychedelic-derived drug candidate, in a Phase I/IIa clinical trial for Alcohol Use Disorder (AUD). Conducted at leading institutions including Yale and Johns Hopkins, the trial aims to evaluate the safety, tolerability, and efficacy of CMND-100 in reducing alcohol cravings and consumption. This marks the first time the...
06-30 13:16
Clearmind Medicine Inc. announced the addition of Hadassah-University Medical Center as a clinical site for its Phase I/IIa trial evaluating CMND-100, an oral drug candidate for treating Alcohol Use Disorder (AUD). The trial, led by Prof. Yossi Karko, joins prestigious institutions like Yale and Johns Hopkins. CMND-100 aims to address AUD, a significant global health issue affecting over 280 million people, with limited current treatment options....
06-27 13:00
Clearmind Medicine Inc. has initiated a Phase I/IIa clinical trial for CMND-100, an oral psychedelic-derived drug candidate aimed at treating Alcohol Use Disorder (AUD). The first patient was enrolled at Yale School of Medicine, marking a significant milestone. The trial evaluates the safety, tolerability, and pharmacokinetics of CMND-100, with preliminary assessments of its potential to reduce alcohol cravings and consumption. CEO Adi Zuloff-Sha...
06-25 11:48